Turn Therapeutics Inc. Share-based Payment Arrangement, Expense
Turn Therapeutics Inc. (TTRX) reported Share-based Payment Arrangement, Expense of $155.83 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-05-11
- Turn Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $155.83K, a 103.49% increase year-over-year.
- Turn Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $157.13K, a 349.20% increase year-over-year.
- Turn Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $76.58K.
- Turn Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2024-12-31 was $34.98K.
- Turn Therapeutics Inc. share-based payment arrangement, expense for fiscal 2025 was $320.00K, a 8.57% decline from fiscal 2024.
- Turn Therapeutics Inc. share-based payment arrangement, expense for fiscal 2024 was $350.00K.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $155.83K 10-Q · filed 2026-05-11 | $312.96K derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2025-12-31 | $157.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $320.00K 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $162.87K 10-Q · filed 2025-11-13 | |||
| 2025-03-31 | $76.58K 10-Q · filed 2026-05-11 | $111.56K derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2024-12-31 | $34.98K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $350.00K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $315.02K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |